Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis

Br J Cancer. 2004 Dec 13;91(12):1990-2. doi: 10.1038/sj.bjc.6602269.

Abstract

Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Blotting, Southern
  • DNA-Binding Proteins / genetics*
  • Dexamethasone / administration & dosage
  • Epstein-Barr Virus Infections / complications
  • Etoposide / adverse effects
  • Gene Rearrangement
  • Histiocytosis, Non-Langerhans-Cell / drug therapy*
  • Histiocytosis, Non-Langerhans-Cell / etiology
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Infant
  • Leukemia, Myelomonocytic, Acute / etiology*
  • Male
  • Methotrexate / administration & dosage
  • Myeloid-Lymphoid Leukemia Protein
  • Neoplasms, Second Primary / genetics*
  • Nucleic Acid Synthesis Inhibitors / adverse effects*
  • Polymerase Chain Reaction
  • Proto-Oncogenes / genetics*
  • Time Factors
  • Topoisomerase II Inhibitors
  • Transcription Factors / genetics*

Substances

  • DNA-Binding Proteins
  • KMT2A protein, human
  • Nucleic Acid Synthesis Inhibitors
  • Topoisomerase II Inhibitors
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Etoposide
  • Dexamethasone
  • Histone-Lysine N-Methyltransferase
  • Methotrexate